Association of PD-L1 expression with clinicopathologic features and overall survival in patients with non-small-cell lung cancer

作者：Zhou, Yan; Liu, Xianxun; Hu, Zhangguo; Zhong, Runbo; Han, Baohui^*; Zhong, Hua^*

来源：International Journal of Clinical and Experimental Pathology, 2017, 10(2): 1954-1961.

• Lung cancer
• PD-1
• PD-L1
• EGFR

Multiple lines ofevidence showed that non-small cell lung cancer (NSCLC) patients had improved clinical outcomes when immune checkpoint was blocked. Programmed death receptor 1 (PD-L1) is one of the most extensively studied molecules that are highly implicated in the response to immunotherapy in NSCLC. However, studies that report the prevalence of PD-L1 expression in NSCLC and address their association are still scarce. This study was aimed to complement this vacancy by determining the prevalence of PD-L1 expression in NSCLC and analyzing its associations with clinical pathologic parameters and outcome. Totally, 139 operated patient sat stage II-III NSCLC were enrolled. For malin-fixed and paraffin-embedded (FFPE) tumour sections were reviewed and stained with PD-L1 antibody. The correlations between expression of PD-L1 and clinical pathologic features and overall survival (OS) were analyzed. PD-L1 expression was detectedin 61.8% of NSCLC. No significant relationship was found between PD-L1 expression and patients' gender, age, smoking history, stage, subtype or EGFR status. Furthermore, the median OS of PD-L1 positive patients (49.3 months, 95% CI: 44.5-54.2) was longer than PD-L1 negative patients (40.9 months, 95% CI: 35.3-46.5), P = 0.028. PD-L1 expression is correlated with a longer survival time, indicating its potential diagnostic value in assessment for operated patients with stage II-III NSCLC. Given the inconsistency in other related studies, some other factors beyond this study's scope may also affect immune response of NSCLC and thus more comprehensive researches are needed.

• 出版日期2017
• 单位上海交通大学